Clinical Trial Update: Study Evaluating AGG-523 in Subjects With Osteoarthritis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AGG-523 in osteoarthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• AGG-523

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Osteoarthritis | Phase 1 | Status: COMPLETED